MSMaria De Salvo

Maria De Salvo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maria De Salvo has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS

    by Roberta Ciarapica, Elena Carcarino, Laura Adesso, Maria De Salvo, Giorgia Bracaglia, Pier Paolo Leoncini, Alessandra Dall’agnese, Federica Verginelli, Giuseppe M Milano, Renata Boldrini, et al.

    Embryonal Rhabdomyosarcoma (RMS) is a pediatric soft-tissue sarcoma derived from myogenic precursors that is characterized by a good prognosis in patients with localized disease. Conversely, metastatic tumors often relapse, leading to a dismal outcome. The histone methyltransferase EZH2 epigenetically suppresses skeletal muscle differentiation by repressing the transcription of myogenic genes. Moreover, de-regulated EZH2 expression has been extensively implied in human cancers. We have previously shown that EZH2 is aberrantly over-expressed in RMS primary tumors and cell lines. Moreover, it has been recently reported that EZH2 silencing in RD cells, a recurrence-derived embryonal RMS cell line, favors myofiber-like structures formation in a pro-differentiation context. Here we evaluate whether similar effects can be obtained also in the presence of growth factor-supplemented medium (GM), that mimics a pro-proliferative microenvironment, and by pharmacological targeting of EZH2 in RD cells and in RD tumor xenografts. Embryonal RMS RD cells were cultured in GM and silenced for EZH2 or treated with either the S-adenosylhomocysteine hydrolase inhibitor 3-deazaneplanocin A (DZNep) that induces EZH2 degradation, or with a new class of catalytic EZH2 inhibitors, MC1948 and MC1945, which block the catalytic activity of EZH2. RD cell proliferation and myogenic differentiation were evaluated both in vitro and in vivo. Here we show that EZH2 protein was abnormally expressed in 19 out of 19 (100%) embryonal RMS primary tumors and cell lines compared to their normal counterparts. Genetic down-regulation of EZH2 by silencing in GM condition reduced RD cell proliferation up-regulating p21Cip1. It also resulted in myogenic-like differentiation testified by the up-regulation of myogenic markers Myogenin, MCK and MHC. These effects were reverted by enforced over-expression of a murine Ezh2, highlighting an EZH2-specific effect. Pharmacological inhibition of EZH2 using either DZNep or MC inhibitors phenocopied the genetic knockdown of EZH2 preventing cell proliferation and restoring myogenic differentiation both in vitro and in vivo. These results provide evidence that EZH2 function can be counteracted by pharmacological inhibition in embryonal RMS blocking proliferation even in a pro-proliferative context. They also suggest that this approach could be exploited as a differentiation therapy in adjuvant therapeutic intervention for embryonal RMS.


  • Abstract A29: Notch-dependent modulation of microRNAs in rhabdomyosarcoma

    by Rossella Rota, Roberta Ciarapica, Letizia Da Sacco, Maria De Salvo, Andrea Masotti, Lucio Miele, Franco Locatelli

    Rhabdomyosarcoma (RMS) is a pediatric tumor that originates from skeletal muscle precursors. Therapeutic strategies aimed at restoring the differentiation potential of RMS tumor cells are accepted as anti-cancer approaches. Therefore, pathways involved in skeletal muscle determination are good potential targets. We have recently demonstrated that Notch3 signaling is over-activated in RMS cell lines of both embryonal and alveolar subtype. Down-regulation of Notch3 expression resulted in cell cycle inhibition of RMS alveolar and embryonal cell lines that showed the appearance of multinucleated structures indicative of skeletal muscle-like myotubes in vitro. Moreover, Notch3 knockdown impaired tumor growth in vivo. Here we expand this study evaluating, through microarrays profiling, the expression of microRNAs 48 hours after Notch3 siRNA treatment compared to that of control siRNA. Several up- or down-regulated microRNAs were detected in both RH30 alveolar and RD embryonal cells. The up-regulation of muscle-specific microRNAs such as miR-1, miR-133 and miR-206 was confirmed 24 and 48 hours post-Notch3 depletion by RT-qPCR. Moreover, non-muscle-specific microRNAs such as miR-26a and miR-214 that cooperate to myogenesis were up-regulated as well. Altogether, these preliminary results indicate that Notch3 prevents the differentiation of RMS cells also through down-regulation of pro-myogenic microRNAs. More deep studies are in course to dissect the Notch3-dependent modulation of these small non-coding RNAs in this soft tissue sarcoma. Citation Format: Rossella Rota, Sr., Roberta Ciarapica, Jr., Letizia Da Sacco, Jr., Maria De Salvo, Jr., Andrea Masotti, Sr., Lucio Miele, Sr., Franco Locatelli, Sr. Notch-dependent modulation of microRNAs in rhabdomyosarcoma [abstract]. In: Proceedings of the AACR Special Conference on Noncoding RNAs and Cancer; 2012 Jan 8-11; Miami Beach, FL. Philadelphia (PA): AACR; Cancer Res 2012;72(2 Suppl):Abstract nr A29.